share_log

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target

Benzinga ·  Nov 4 19:16  · Ratings

HC Wainwright & Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $400 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment